title: Evaluation of ototoxicity in children treated for retinoblastoma: preliminary results of a systematic audiological evaluation.
abstract: BACKGROUND
  The objective of this study was to identify the ocurrence of hearing loss in children treated for retinoblastoma using a multidisciplinary approach.
  
  
  METHODS
  Thirty-two children were evaluated pre- and post-treatment. Eleven children were treated exclusively with enucleation, fifteen with carboplatin and six with cisplatin. Otoacoustic emissions were performed with the ILO 88, before and after the treatment.
  
  
  RESULTS
  In our study we found 5 children (24%) with hearing loss among the 21 evaluated. However in the group of children treated with carboplatin (N=15), 1 case (6.6%) presented hearing loss, while among those treated with cisplatin (N=6) we found 4 cases (66.6%) with hearing loss (p=0.0114).
  
  
  CONCLUSIONS
  We concluded that patients who are treated with cisplatin are at risk for developing hearing loss.
authors: Audiology Department, Hospital AC Camargo, Aclimação, Sao Paulo, Brazil. phpliberman@hcancer.org.br
authors: Patricia Helena
authors: PH
authors: Pecora Liberman
authors: Christiane
authors: C
authors: Schultz
authors: María Valéria
authors: MV
authors: Schmidt Goffi-Gómez
authors: Célia B G
authors: CB
authors: Antoneli
authors: Martha
authors: M
authors: Motoro Chojniak
authors: Paulo
authors: P
authors: Eduardo Novaes
references: J Acoust Soc Am. 1978 Nov;64(5):1386-91
references: 744838
references: Braz J Otorhinolaryngol. 2009 Sep-Oct;75(5):634-41
references: 19893928
references: Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1393-402
references: 15817342
references: Med Pediatr Oncol. 1991;19(4):295-300
references: 2056973
references: Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1489-95
references: 11121653
references: Int J Pediatr Otorhinolaryngol. 1993 Jan;25(1-3):73-80
references: 8436482
references: J Otolaryngol. 1994 Jun;23(3):151-9
references: 8064951
references: Ear Hear. 1998 Dec;19(6):434-49
references: 9867292
references: Pediatr Blood Cancer. 2004 Apr;42(4):373-9
references: 14966836
references: Eur J Cancer. 2004 Nov;40(16):2352-4
references: 15519505
references: Otolaryngol Clin North Am. 1978 Oct;11(3):631-50
references: 733250
references: Otolaryngol Head Neck Surg. 1998 May;118(5):584-8
references: 9591854
references: J Pediatr Hematol Oncol. 2004 Oct;26(10):649-655
references: 27811606
references: Pediatr Blood Cancer. 2009 Dec;53(6):1162
references: 19479791
references: J Clin Oncol. 2000 Jan;18(1):12-7
references: 10623688
references: Eur J Cancer. 2004 Nov;40(16):2445-51
references: 15519518
references: J Clin Oncol. 2010 Apr 1;28(10):1788-95
references: 20194861
references: Pediatr Blood Cancer. 2008 Feb;50(2):223-6
references: 17278120
references: Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):86-90
references: 12007945
references: Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1338-44
references: 16863923
references: Eur J Cancer. 1997 Dec;33(14):2368-75
references: 9616283
references: Eur J Cancer. 2006 Mar;42(4):492-500
references: 16376542
references: Pediatr Blood Cancer. 2005 Jul;45(1):32-6
references: 15768383
references: J Pediatr Hematol Oncol. 2006 Jun;28(6):342-5
references: 16794500
references: J Am Acad Audiol. 1998 Aug;9(4):257-62
references: 9733234
references: J Am Acad Audiol. 1994 May;5(3):195-203
references: 8075415